基本信息
浏览量:131
职业迁徙
个人简介
Dr. Nada Jabado is a Professor of Pediatrics and staff physician in the Department of Hematology and Oncology at the Montreal Children’s Hospital. She completed her residency in pediatrics with a specialization in hemato-oncology, obtained a PhD in Immunology in Paris and followed that by a postdoctoral fellowship in biochemistry at McGill. She began her career as an independent investigator at The Research Institute of the McGill University Health Centre in 2003, pioneering a research program in pediatric brain tumours which is now unparalleled. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumours. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1) at amino acid positions K27 (Lysine to Methionine, K27M) and G34 (Glycine to Valine or Arginine, G34V/R). A true clinician-scientist, Dr. Jabado leads a lab comprised of 6 postdoctoral and clinical fellows, 6 graduate students and 5 research assistants/associates. Her ground-breaking work has created a paradigm shift in cancer with the identification of histone mutations in human disease for the first time. This finding has revolutionized the field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetic-driven cancers. This work and other publications in the subject are considered landmark papers (over 3000 citations since 2012).
Dr. Jabado has over 150 peer-reviewed publications to her credit, with an impressive number of senior-author, high-impact publications in such prominent journals as Nature Genetics, Nature, Science and Cancer Cell, to name a few. She established the ICHANGE (International CHildhood Astrocytoma Novel Genomic and Epigenomic) Consortium which groups researchers from 17 countries. This is a unique set of resources which enables the scientific community to explore pediatric brain tumors in depth with the ultimate aim of offering better therapeutic options by providing datasets, international collaborations and access to technology to all members of participating countries.
Dr. Jabado is an international leader in the field of neuro-oncology and cancer, honored by invitations as Keynote and Guest Speaker at top ranked symposia and universities. She has received numerous national and international accolades while garnering prestigious awards throughout her career. She is one of the best-funded investigators at McGill, with grants from CIHR, FRSQ, Genome Canada, NIH, a Large Scale Genomic grant from Genome Canada as well as funding from philanthropic organizations. She was recently inducted as a Fellow to the Royal Society of Canada.
Dr. Jabado is part of a rare breed of physicians that can actively link research to the bedside, a true clinician scientist. Her dedication to scientific research in pediatric brain tumours and her passion for the patients in her care are inspiring and infectious to colleagues and trainees alike. Her coworkers describe her as The Tasmanian Devil, a moving force of nature that can uproot entire schools of thought with gale-force winds. Anyone who has witnessed her speak in public will also attest to this phenomenon. Legend has it that she lives on coffee and chocolates. Dr. Jabado considers downtime as time spent racing the ski slopes with her physician husband and three teenage children who are a family of avid skiers.
As an independent Principal Investigator, Dr. Jabado's has embarked on elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults. These are deadly brain tumours that originate in brain and include glioblastomas (GBM, the highest grade of astrocytomas), which are one of the deadliest cancers in humans. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. They also identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). These mutations lead to amino acid substitutions at key residues and are tightly correlated with a distinct global DNA methylation pattern, neuroanatomical locations and age specificities. Their findings position them as leaders in the field of HGA, at the forefront of significant breakthroughs for this deadly brain tumor. Crucial impediments to progress are the lack of reliable in vitro and in vivo models for these “oncohistones” and understanding their effects in driving tumors and therapeutic resistance. they aim to identify events affected downstream of each mutation, and validate targets in their new models to better advise the use of experimental or pipeline drug(s) or drug combinations that could be rapidly translated into clinical trials. Ultimately, based on their findings, patients could be stratified based on their genetic/molecular signature, and assigned to a beneficial therapeutic strategy, bringing needed effective interventions in this devastating cancer. Additionally, they established a TCGA-like initiative by creating the International CHildhood Astrocytoma INtegrated Genomic and Epigenomic (ICHANGE) Consortium. This is a unique set of resources which enables the scientific world to investigate astrocytomas in children. It includes databases and access to technology as well as international collaborations from 15 participating countries, including ~1500 annotated glioma tissue samples representative of all grades and ages.
Dr. Jabado has over 150 peer-reviewed publications to her credit, with an impressive number of senior-author, high-impact publications in such prominent journals as Nature Genetics, Nature, Science and Cancer Cell, to name a few. She established the ICHANGE (International CHildhood Astrocytoma Novel Genomic and Epigenomic) Consortium which groups researchers from 17 countries. This is a unique set of resources which enables the scientific community to explore pediatric brain tumors in depth with the ultimate aim of offering better therapeutic options by providing datasets, international collaborations and access to technology to all members of participating countries.
Dr. Jabado is an international leader in the field of neuro-oncology and cancer, honored by invitations as Keynote and Guest Speaker at top ranked symposia and universities. She has received numerous national and international accolades while garnering prestigious awards throughout her career. She is one of the best-funded investigators at McGill, with grants from CIHR, FRSQ, Genome Canada, NIH, a Large Scale Genomic grant from Genome Canada as well as funding from philanthropic organizations. She was recently inducted as a Fellow to the Royal Society of Canada.
Dr. Jabado is part of a rare breed of physicians that can actively link research to the bedside, a true clinician scientist. Her dedication to scientific research in pediatric brain tumours and her passion for the patients in her care are inspiring and infectious to colleagues and trainees alike. Her coworkers describe her as The Tasmanian Devil, a moving force of nature that can uproot entire schools of thought with gale-force winds. Anyone who has witnessed her speak in public will also attest to this phenomenon. Legend has it that she lives on coffee and chocolates. Dr. Jabado considers downtime as time spent racing the ski slopes with her physician husband and three teenage children who are a family of avid skiers.
As an independent Principal Investigator, Dr. Jabado's has embarked on elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults. These are deadly brain tumours that originate in brain and include glioblastomas (GBM, the highest grade of astrocytomas), which are one of the deadliest cancers in humans. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. They also identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). These mutations lead to amino acid substitutions at key residues and are tightly correlated with a distinct global DNA methylation pattern, neuroanatomical locations and age specificities. Their findings position them as leaders in the field of HGA, at the forefront of significant breakthroughs for this deadly brain tumor. Crucial impediments to progress are the lack of reliable in vitro and in vivo models for these “oncohistones” and understanding their effects in driving tumors and therapeutic resistance. they aim to identify events affected downstream of each mutation, and validate targets in their new models to better advise the use of experimental or pipeline drug(s) or drug combinations that could be rapidly translated into clinical trials. Ultimately, based on their findings, patients could be stratified based on their genetic/molecular signature, and assigned to a beneficial therapeutic strategy, bringing needed effective interventions in this devastating cancer. Additionally, they established a TCGA-like initiative by creating the International CHildhood Astrocytoma INtegrated Genomic and Epigenomic (ICHANGE) Consortium. This is a unique set of resources which enables the scientific world to investigate astrocytomas in children. It includes databases and access to technology as well as international collaborations from 15 participating countries, including ~1500 annotated glioma tissue samples representative of all grades and ages.
研究兴趣
论文共 52 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 5_Supplement_1 (2024)
Alexandre Lachance, Evan Dimentberg,Sidong Huang, Samuel Bergeron-Gravel,Éric Bouffet,Adriana Fonseca,Louis Crevier, Stephan Saikali, Catherine Bourget, Panagiota Giannakouros,Damien Faury,Nada Jabado,
Child's Nervous Systempp.1-5, (2024)
Ricardo Santiago Gomez, Ahmed El Mouatani,Filipe Fideles Duarte-Andrade,Thais dos Santos Fontes Pereira,Leticia Martins Guimara,Tenzin Gayden,Damien Faury,Emily M. Nakada,Sylvie Langlois,Daniel Sinnett,Wagner Henriques de Castro, Marina Gonsalves Diniz,
MODERN PATHOLOGYno. 2 (2024): 100388-100388
Sayanthen Sathyakumar, Matthew Martinez,Sébastien Perreault,Geneviève Legault,Eric Bouffet,Nada Jabado,Valérie Larouche,Samuele Renzi
European Journal of Pediatricspp.1-14, (2024)
Cancer Researchno. 6_Supplement (2024): 2648-2648
Eve Lalancette,Édith Cantin,Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand,Dorsa Sadat Kiaei,Valérie Larouche,Uri Tabori,Cynthia Hawkins,Benjamin Ellezam,Jean-Claude Décarie,Yves Théoret,
Journal of Neuro-Oncologypp.1-8, (2024)
NEURO-ONCOLOGY (2023)
引用0浏览0引用
0
0
Neuro-Oncologyno. Supplement_1 (2023): i20-i21
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn